Update information

Update information

July 2022: We have reviewed the evidence on assessment, management and follow-up for people with melanoma. These recommendations are marked [2022].

We have also made some changes without an evidence review:

  • Immunomodulators were added to recommendation 1.2.3 and wording was added to clarify seeking specialist team advice for people who are having immunosuppressive or immunomodulatory treatments.

  • The 2015 recommendation on minimising or avoiding immunosuppressants was deleted because it was superseded by the amended recommendation 1.2.3.

  • Examples of ablative treatments were removed from recommendation 1.8.2.

  • Wording was added to recommendation 1.8.5 to clarify that people with melanoma and brain metastases should be referred to a neuro-oncology team.

These recommendations are marked [2015, amended 2022].

Recommendations marked [2015] last had an evidence review in 2015. In some cases minor changes have been made to the wording to bring the language and style up to date, without changing the meaning.

Minor changes since publication

January 2024: We made minor changes to recommendations 1.3.9 and 1.3.10 on BRAF analysis of primary melanoma tissue samples to bring them in line with the NICE technology appraisal guidance on pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma.

July 2023: We amended a heading in section 1.8 to separate treatments for untreated and previously treated stage IV and unresectable stage III melanoma.

July 2019: We added option grids to help with discussion of potential treatments. Links to technology appraisal guidance on the NICE topic page for melanoma added to sections 1.7 and 1.8.

ISBN: 978-1-4731-1322-0

  • National Institute for Health and Care Excellence (NICE)